



2024

BLOOM BURTON & CO.
HEALTHCARE
INVESTOR
CONFERENCE

APRIL 16-17





BLOOM BURTON & CO.
15TH ANNIVERSARY

BLOOM BURTON & CO.

Exists to accelerate returns in the healthcare sector for both companies and investors. There is no greater illustration of the power of our platform than this conference, which has grown into Canada's flagship healthcare investment and networking event over the past decade.

TABLE OF CONTENTS

About	3
Agenda	4
Keynote Speaker	6
Investing in Commercial-Stage Healthcare Companies Panel ..	8
Investing in R&D-Stage Healthcare Companies Panel	11
Presenting Companies	16
About Bloom Burton & Co.....	54
Sponsors	58
Conference Information	60

WIFI

Network Name: **Bloom Burton & Co.**

Access Code: **BBHIC2024**





2024 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE

The 2024 Bloom Burton & Co. Healthcare Investor Conference takes place on April 16-17, 2024 at the Metro Toronto Convention Centre.

Approximately 66 of Canada's premier and most promising publicly-traded and private companies in the healthcare industry are invited to attend and present to our audience of Canadian, U.S. and international investors.

At the conference, investors and company management have the opportunity to meet one-on-one. We also provide a stage for industry leaders to discuss the latest news and share insights on the ups and downs of the market and the state of the global healthcare industry.



AGENDA

Tuesday, April 16

Registration opens at 8:00 AM

8:30 AM	Breakfast and Opening Remarks			PLENARY ROOM 106/107
9:30 AM	Toronto Stock Exchange Opening			PLENARY ROOM 106/107
	ROOM 104 C/D		ROOM 104 B	ROOM 104 A
9:30 AM	NASDAQ: XENE Xenon Pharmaceuticals BIOTECHNOLOGY	9:30 AM	NASDAQ: PROF / TSX: PRN Profound Medical MEDICAL TECHNOLOGY	9:30 AM PRIVATE FORUS Therapeutics SPECIALTY PHARMACEUTICALS
10:00 AM	NASDAQ: ABCL AbCellera Biologics BIOTECHNOLOGY	10:00 AM	TSX: HTL Hamilton Thorne MEDICAL TECHNOLOGY	10:00 AM PRIVATE Kye Pharmaceuticals SPECIALTY PHARMACEUTICALS
10:30 AM	TSX: EPRX Eupraxia Pharmaceuticals BIOTECHNOLOGY	10:30 AM	TSX: MBX Microbix Biosystems MEDICAL TECHNOLOGY	10:30 AM TSX: GUD Knight Therapeutics SPECIALTY PHARMACEUTICALS
11:00 AM	TSX: MDNA Medicenna Therapeutics BIOTECHNOLOGY	11:00 AM	PRIVATE Intellijoint Surgical MEDICAL TECHNOLOGY	11:00 AM PRIVATE 35Pharma BIOTECHNOLOGY
11:30 AM	TSX: MSCL Satellos Bioscience BIOTECHNOLOGY	11:30 AM	PRIVATE Synaptive Medical MEDICAL TECHNOLOGY	11:30 AM PRIVATE Ventus Therapeutics BIOTECHNOLOGY
12:00 PM	Lunch			PLENARY ROOM 106/107
12:30 PM	Keynote Speaker Eli Casdin, Chief Investment Officer and Founder (Casdin Capital)			PLENARY ROOM 106/107
	ROOM 104 C/D		ROOM 104 B	ROOM 104 A
1:30 PM	NYSE: CYBN / NEO:CYBN Cybin BIOTECHNOLOGY	1:30 PM	PRIVATE Virica Biotech TOOLS	1:30 PM PRIVATE Congruence Therapeutics BIOTECHNOLOGY
2:00 PM	NYSE: ZYME Zymeworks BIOTECHNOLOGY	2:00 PM	PRIVATE AtomVie Global Radiopharma HEALTHCARE SERVICES/DIGITAL HEALTH	2:00 PM PRIVATE Abdera Therapeutics BIOTECHNOLOGY
2:30 PM	NASDAQ: EPIX ESSA Pharma BIOTECHNOLOGY	2:30 PM	PRIVATE Exact Imaging MEDICAL TECHNOLOGY	2:30 PM PRIVATE Zucara Therapeutics BIOTECHNOLOGY
3:00 PM	NASDAQ: ENGN enGene BIOTECHNOLOGY	3:00 PM	PRIVATE Panthera Dental MEDICAL TECHNOLOGY	3:00 PM PRIVATE Thryv Therapeutics BIOTECHNOLOGY
3:30 PM	NASDAQ: RPTX Repare Therapeutics BIOTECHNOLOGY	3:30 PM	PRIVATE Adaptiiv Medical Technologies MEDICAL TECHNOLOGY	NASDAQ: AEZS / TSX: AEZS Ceapro BIOTECHNOLOGY
4:00 PM	NASDAQ: AUPH Aurinia Pharmaceuticals BIOTECHNOLOGY	4:00 PM	PRIVATE Orpyx MEDICAL TECHNOLOGY	CSE: BETR BetterLife Pharmaceuticals BIOTECHNOLOGY
5:00 PM	Bloom Burton & Co. Cocktail Reception at Steam Whistle Brewing			STEAM WHISTLE BREWING, 255 BREMNER BLVD

1X1 Meeting Sessions - Room 105
9:30 AM-12:00 PM | 1:30 PM-5:00 PM
on April 16 and April 17.

Wednesday, April 17

Registration opens at 8:00 AM

8:15 AM		Breakfast and Opening Remarks			PLENARY ROOM 106/107	
8:30 AM		Investing in Commercial-Stage Healthcare Companies Panel Sandip Agarwala (Blue Owl Capital), Ryan Drant (Questa Capital), Bijan Salehzadeh (NaviMed Capital), and Anya Schiess (J.P. Morgan)			PLENARY ROOM 106/107	
ROOM 104 C/D		ROOM 104 B		ROOM 104 A		
9:30 AM	PRIVATE Pharmascience <small>SPECIALTY PHARMACEUTICALS</small>	9:30 AM	PRIVATE Canary Medical <small>MEDICAL TECHNOLOGY</small>	9:30 AM	TSX: SVA Sernova <small>BIOTECHNOLOGY</small>	
10:00 AM	PRIVATE Searchlight Pharma <small>SPECIALTY PHARMACEUTICALS</small>	10:00 AM	PRIVATE AlayaCare <small>HEALTHCARE SERVICES/DIGITAL HEALTH</small>	10:00 AM	NASDAQ: THTX / TSX: TH Theratechnologies <small>BIOTECHNOLOGY</small>	
10:30 AM	TSX: DHT.UN / DHT.U DRI Healthcare Trust <small>SPECIALTY PHARMACEUTICALS</small>	10:30 AM	PRIVATE SRx Health Solutions <small>HEALTHCARE SERVICES/DIGITAL HEALTH</small>	10:30 AM	NASDAQ: PMN ProMIS Neurosciences <small>BIOTECHNOLOGY</small>	
11:00 AM	PRIVATE Xediton Pharmaceuticals <small>SPECIALTY PHARMACEUTICALS</small>	11:00 AM	TSX-V: NPTH NeuPath Health <small>HEALTHCARE SERVICES/DIGITAL HEALTH</small>	11:00 AM	NASDAQ: EDSA Edesa Biotech <small>BIOTECHNOLOGY</small>	
11:30 AM	PRIVATE Apotex <small>SPECIALTY PHARMACEUTICALS</small>	11:30 AM	TSX-V: NEWU Newtopia <small>HEALTHCARE SERVICES/DIGITAL HEALTH</small>	11:30 AM	PRIVATE KalGene <small>BIOTECHNOLOGY</small>	

12:00 PM		Lunch			PLENARY ROOM 106/107	
12:30 PM		Investing in R&D-Stage Healthcare Companies Panel Nessian Bermingham (Khosla Ventures), Craig Gordon (GordonMD Global Investments), Karan Takhar (Matrix Capital Management), and Asish Xavier (J & J Innovation - JJDC)			PLENARY ROOM 106/107	

ROOM 104 C/D		ROOM 104 B		ROOM 104 A	
1:30 PM	TSX: WELL WELL Health Technologies <small>HEALTHCARE SERVICES/DIGITAL HEALTH</small>	1:30 PM	TSX: MDP Medexus Pharma <small>SPECIALTY PHARMACEUTICALS</small>	1:30 PM	PRIVATE Notch Therapeutics <small>BIOTECHNOLOGY</small>
2:00 PM	TSX: DNTL dentalcorp <small>HEALTHCARE SERVICES/DIGITAL HEALTH</small>	2:00 PM	TSX: HLS HLS Therapeutics <small>SPECIALTY PHARMACEUTICALS</small>	2:00 PM	PRIVATE Gandeeva Therapeutics <small>BIOTECHNOLOGY</small>
2:30 PM	TSX: VHI VitalHub <small>HEALTHCARE SERVICES/DIGITAL HEALTH</small>	2:30 PM	TSX: CPH Cipher Pharmaceuticals <small>SPECIALTY PHARMACEUTICALS</small>	2:30 PM	PRIVATE Find Therapeutics <small>BIOTECHNOLOGY</small>
3:00 PM	TSX: CRRX CareRx <small>HEALTHCARE SERVICES/DIGITAL HEALTH</small>	3:00 PM	TSX-V: WOLF Grey Wolf Animal Health <small>SPECIALTY PHARMACEUTICALS</small>	3:00 PM	PRIVATE Entos Pharmaceuticals <small>BIOTECHNOLOGY</small>
3:30 PM	TSX: AIDX HEALWELL AI <small>HEALTHCARE SERVICES/DIGITAL HEALTH</small>	3:30 PM	TSX-V: RX BioSyent <small>SPECIALTY PHARMACEUTICALS</small>	3:30 PM	PRIVATE Domain Therapeutics <small>BIOTECHNOLOGY</small>
4:00 PM	TSX-V: LSL LSL Pharma Group <small>SPECIALTY PHARMACEUTICALS</small>	4:00 PM	TSX: VPH Valeo Pharma <small>SPECIALTY PHARMACEUTICALS</small>	4:00 PM	PRIVATE Mesentech <small>BIOTECHNOLOGY</small>



KEYNOTE SPEAKER

ELI CASDIN

**Chief Investment Officer and Founder
of Casdin Capital**



Tuesday April 16, 2024

12:30 PM-1:30 PM

Plenary Room 106/107



ABOUT ELI CASDIN

Eli Casdin founded Casdin Capital in 2011 and serves as Chief Investment Officer and Founder. Casdin Capital engages as productive investor-partners, helping to fuel the visions of industry leaders by adding expertise and experience to their funding. Focused on emergent technologies in Life Sciences for more than two decades, Eli Casdin has been active in both private and public capital markets, following a passion for analyzing and investing in new technologies and business models within the Life Sciences and healthcare industry.

Prior to founding Casdin Capital, Eli Casdin served as vice president at Alliance Bernstein's thematic investment arm, focusing personally on new technologies for the life sciences and healthcare sectors. While there he authored the 2011 black book, "The Dawn of Molecular Medicine," detailing the (then) early-yet-accelerating wave of innovations transforming healthcare and creating opportunity for investors from testing to targeted medicine, diagnostics to industrial agriculture.

Earlier, he worked as a financial analyst at Bear Stearns and Cooper Hill Partners, a healthcare-focused investment firm.

Eli Casdin earned a B.S. from Columbia University and an MBA from Columbia Business School. Today, he serves as a director or an observer on various boards for a number of public and private life sciences companies, trade groups and academic institutes including Rockefeller University, the New York Genome Center Board and The Columbia University School of General Studies Board of Visitors.





Investing in Commercial-Stage Healthcare Companies Panel

Sandip Agarwala

Blue Owl Capital

Ryan Drant

Questa Capital

Bijan Salehizadeh

NaviMed Capital

Anya Schiess

J.P. Morgan

Wednesday, April 17, 2024

8:30 AM-9:30 AM

Plenary Room 106/107

INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES PANEL



SANDIP AGARWALA

Managing Director
Blue Owl Capital

Sandip Agarwala focuses on life sciences credit, royalty and growth equity investments.

Before joining Blue Owl, Sandip was a Managing Director at Longitude Capital, a life sciences focused investment firm. Prior to that, he was a Vice President at Auken Therapeutics Management.

Sandip began his career as a management consultant with The Boston Consulting Group and The Frankel Group. Sandip received his M.B.A. in Finance and Healthcare Management from The Wharton School and holds a BSE in Systems Science and Engineering from the University of Pennsylvania.

RYAN DRANT

Founder and Managing Partner
Questa Capital

Ryan Drant is the Founder and Managing Partner at Questa Capital. He has been actively investing in the healthcare industry since 1996. He specializes in investments in the healthcare technology, healthcare services and medical device sectors. During his investment career, he has served on the board of directors of 46 companies and has directed the deployment of more than \$1 billion in equity capital.

Ryan has been named four times to the Forbes Midas List of the top venture capital investors. Prior to founding Questa, Ryan was a General Partner at New Enterprise Associates (NEA) where he joined in 1996, became a general partner in 2004 and served on the firm's Investment Committee for 11 years spanning four funds totaling \$8 billion in total capital. He served as head of the firm's global healthcare investing practice and served as a member of NEA's four-person management committee.

Previously, Ryan held positions with Alex. Brown & Sons and Arthur Andersen & Co. Ryan graduated from Stanford University with a BA degree in Political Science.

INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES PANEL



BIJAN SALEHIZADEH

Managing Director and Co-Founder
NaviMed Capital

Bijan Salehizadeh has over 20 years of healthcare operating and investment experience. At NaviMed, he sits on the firm's Investment Committee and is responsible for leading investments and overseeing portfolio companies with a particular focus on healthcare providers and pharmaceutical services. Prior to co-founding NaviMed Capital, he was a General Partner at Highland Capital Partners, where he focused on growth stage healthcare investments.

Bijan led NaviMed's investments in and currently serves on the Board of Directors of Advantage Surgical & Wound Care. He also serves on the Board of Directors of OPN Healthcare, Aledade. Bijan previously led NaviMed's investments in CenterPointe Behavioral Health System (sold to Acadia Healthcare), The CM Group (sold to OPEN Health), Lighthouse Lab Services (majority recapitalized), and Velocity Clinical Research (sold).

He also has served on the Board of Directors of several companies including Auris Health, BARRX Medical, Hyperion Therapeutics, Lumere, and Opgen.

Bijan holds an AB in Molecular Biology from Princeton University, an MD and Master's in Science in Health Policy from Columbia University, and an MBA from Harvard Business School. He is also a graduate of the Kauffman Fellows Program.



ANYA SCHIESS

Co-Managing Partner
J.P. Morgan

Anya Schiess is Co-Managing Partner of Life Science Private Capital ("LSPC") within J.P. Morgan Private Capital, a division of J.P. Morgan Global Alternatives in J.P. Morgan Asset Management. Anya joined J.P. Morgan Private Capital in 2022. Alongside Gaurav Gupta, Anya is co-managing partner of the LSPC platform, which leverages the global scale, robust healthcare service ecosystem and healthcare data intelligence of J.P. Morgan to invest in life sciences and healthcare companies.

Prior to joining LSPC, Anya was previously a founder and General Partner of Healthy Ventures. Previously, Anya was a venture capitalist at Thomas, Mc Nerney & Partners where her focus included biopharmaceuticals, medical devices, and genomic technology. Anya has co-founded, helped build, or served on the boards of over 30 companies. Prior to investing, Anya was a healthcare operator and led strategy and business development for Cardinal Health's medical services, distribution, and laboratory businesses as well as several sales & marketing leadership roles at Medtronic.

Anya earned a B.A. cum laude from Princeton University and an M.B.A. with honors from The Wharton School at the University of Pennsylvania.



Investing in R&D-Stage Healthcare Companies Panel

Nessan Bermingham

Khosla Ventures

Craig Gordon

GordonMD Global Investments

Karan Takhar

Matrix Capital Management

Asish Xavier

Johnson & Johnson Innovation – JJDC

Wednesday, April 17, 2024

12:30 PM-1:30 PM

Plenary Room 106/107



INVESTING IN R&D-STAGE HEALTHCARE COMPANIES PANEL



NESSAN BERMINGHAM

Operating Partner
Khosla Ventures

Nesson Bermingham is an Operating Partner at Khosla Ventures focused on life science companies with an emphasis on nucleic acid editing, novel delivery systems, gene and cell therapy, novel target identification and data analytics for drug discovery and development.

Having founded multiple companies in the life sciences realm, Nesson is a serial biotech entrepreneur and investor. Most notable among his companies are Intellia Therapeutics, a top-10 biotech startup in 2014, Triplet Therapeutics, and Korro Bio. At Intellia, Nesson served as president and CEO from inception through 2017.

Nesson also held investment roles at Atlas Venture and Omega Fund Management, where he successfully invested in and managed multiple investments across the United States and Europe. He is currently executive chair at Everyone Medicines, Liberate Bio, Korro Bio and Stylus Biomedicine. He also currently sits on the board of, Deep Genomics, Focal Medical and Ochre Bio and is a board observer with CHARM Therapeutics.

Previously he was a member of the equity research team at UBS, an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London, and was a Howard Hughes Associate Fellow at Baylor College of Medicine.



CRAIG GORDON

Founder, Chief Executive Officer, and Chief Investment Officer
GordonMD Global Investments

Craig D. Gordon is the founder of GordonMD Global, a private and public long-biased global biopharmaceutical investment firm.

Prior to establishing his own firm, he was an Equity Investment Analyst at The Capital Group for over ten years with research and investment responsibilities for U.S. and Japanese biotechnology and pharmaceutical companies. Before joining Capital, he was a biotechnology equity research analyst and associate for the Cowen Group in New York.

Craig holds an MBA from Duke University's Fuqua School of Business; a doctor of medicine (with research distinction) and Medical Resident Teaching Award from the University of Miami, Miller School of Medicine and Jackson Memorial Hospital, respectively; completed his rheumatology training at Duke Medical Center; and holds a bachelor's degree (with distinction) in economics from Cornell University. Craig lives in Los Angeles

INVESTING IN R&D-STAGE HEALTHCARE COMPANIES PANEL



KARAN TAKHAR

Senior Managing Director,
Head of Life Sciences Investing
Matrix Capital Management

Karan Takhar is a Senior Managing Director and the head of Life Sciences investing at Matrix Capital Management, an investment fund focused on technology and life sciences.

Karan received a Bachelor of Sciences in Economics and Mathematics from the Massachusetts Institute of Technology.

ASISH XAVIER

Vice President, Venture Investments
Johnson & Johnson Innovation – JJDC

Asish Xavier serves as the Vice President, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC). He is based at the Johnson & Johnson Innovation Center in Brisbane, CA. Asish focuses on investments in biotechnology, precision diagnostics, data science and machine learning. Asish joined JJDC in 2004 and has led or co-led investments in over 30 biotech, diagnostics, data science, machine learning and medtech companies.

Asish received a Ph.D. in Chemical Engineering from the University of Houston and an MBA from The Wharton School of the University of Pennsylvania, where he graduated with honors. He received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. Asish was a postdoctoral research fellow in the Department of Chemistry at the Johns Hopkins University.

Outside work, Asish enjoys reading, traveling, and being outdoors with his family. He is passionate about science and helping others, and mentors students and entrepreneurs. Asish is a die-hard sports nut, especially a cricket fanatic.

**BLOOM BURTON & CO.
HEALTHCARE INVESTOR CONFERENCE**

Metro Toronto Convention Centre

April 16-17, 2024

**COCKTAIL
RECEPTION**


APRIL 16, 2024

**STEAM WHISTLE BREWING
255 BREMNER BLVD.**

TORONTO, ON M5V 3M9

DOORS OPEN AT 5:00 PM





PRESENTING COMPANIES

This year's Bloom Burton & Co. Healthcare Investor Conference hosts 66 of Canada's premier and most promising publicly-traded and private companies in the healthcare industry in the following five areas.





BIOTECHNOLOGY

HEALTHCARE SERVICES/DIGITAL HEALTH

MEDICAL TECHNOLOGY

SPECIALTY PHARMACEUTICALS

TOOLS

35Pharma

Tuesday, April 16, 2024 | 11:00 AM

Room 104 A

35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment of Pulmonary Hypertension, Heart Failure and Obesity. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta ligands while sparing beneficial homeostatic ligands.

AbCellera Biologics

Tuesday, April 16, 2024 | 10:00 AM

Room 104 C/D

AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera's engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development.

Abdera Therapeutics

Tuesday, April 16, 2024 | 2:00 PM
Room 104 A



Abdera Therapeutics is a biopharmaceutical company leveraging antibody engineering to design and develop new precision radiopharmaceuticals for cancer. Abdera's Radio Optimized Vector Engineering (ROVER™) platform enables the company to engineer potential best-in-class therapies for both clinically validated and novel targets that deliver potent radioisotopes capable of emitting alpha or beta particles to selectively destroy cancer cells. Abdera's lead program targets DLL3 for the treatment of small cell lung cancer and other solid tumors.

Adaptiiv Medical Technologies

Tuesday, April 16, 2024 | 3:30 PM
Room 104 B



Adaptiiv Medical Technologies Inc. provides proprietary, regulatory cleared software that integrates with clinical workflows to digitally design, fabricate, and deliver patient-specific 3D printed medical devices that improve clinical precision and the patient experience. Headquartered in Halifax, Nova Scotia, Canada, Adaptiiv software has FDA 510(k) clearance and has received a CE Mark. The company's solution is currently used in a clinical setting by clients in 18 countries.

AlayaCare

Wednesday, April 17, 2024 | 10:00 AM
Room 104 B



AlayaCare is an end-to-end software platform for public, private, non-profit, and community home-based care organizations that manages the entire client lifecycle, including needs assessments, care plans, scheduling, visit and route optimization, and visit verification. Founded in 2014 and now with over 500 employees, AlayaCare combines traditional in-home and virtual care solutions that enable care providers to lower the cost of care and achieve better outcomes for their clients.

Apotex

Wednesday, April 17, 2024 | 11:30 AM
Room 104 C/D



Apotex is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs nearly 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the United States, Mexico, and India.

AtomVie Global Radiopharma

Tuesday, April 16 2024 | 2:00 PM

Room 104 B

AtomVie Global Radiopharma (AtomVie) is a global leading CDMO for the GMP manufacturing and global distribution of clinical and commercial radiopharmaceuticals offering the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. Following its Series A financing of \$90M, AtomVie is building a 72,000 sq.ft. scalable manufacturing facility with 10 times higher capacity than its current facility. AtomVie is currently pre-selling clinical and commercial capacity and cleanrooms for its new facility.

Aurinia Pharmaceuticals

Tuesday, April 16 2024 | 4:00 PM

Room 104 C/D

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company's head office is in Edmonton, Alberta and its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.

BetterLife Pharmaceuticals

Tuesday, April 16 2024 | 4:00 PM
Room 104 A



BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and noncontrolled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife's pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency. BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

BioSyent

Wednesday, April 17, 2024 | 3:30 PM
Room 104 B



BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

Canary Medical

Wednesday, April 17, 2024 | 9:30 AM

Room 104 B

Canary Medical is a medical data company focused on the development and commercialization of its patented implantable sensor technology and complementary data and analytics ecosystem. In 2021, Canary Medical introduced canturio™te, the world's first "smart knee" tibial extension, which is implanted in the body where it monitors patient activity and joint performance, and transmits data to the cloud, autonomously, requiring almost no patient compliance or physician involvement. The Company was conceived and created with the vision that healthcare transformation requires reliable and cost-effective healthcare data and that the effective monitoring and analysis of that data will produce better outcomes for patients at lower costs. Canary Medical is led by a team of experienced entrepreneurs, researchers and data scientists globally regarded for their expertise in medical device design, development and data informatics.

CareRx

Wednesday, April 17, 2024 | 3:00 PM

Room 104 C/D

CareRx is Canada's leading provider of pharmacy services to seniors living communities. We serve approximately 94,000 residents in over 1,500 seniors and other congregate care communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimes. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.

BIOTECHNOLOGY

NASDAQ: AEZS / TSX: AEZS

Ceapro

Tuesday, April 16, 2024 | 3:30 PM

Room 104 A



Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

SPECIALTY PHARMACEUTICALS

TSX: CPH

Cipher Pharmaceuticals

Wednesday, April 17, 2024 | 2:30 PM

Room 104 B



Cipher Pharmaceuticals is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America.

Congruence Therapeutics

Tuesday, April 16, 2024 | 1:30 PM

Room 104 AThe logo for Congruence TX, featuring the word "congruence" in a lowercase, sans-serif font with a stylized 'c' and 'g', followed by "TX" in a smaller, uppercase font.

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.

Cybin

Tuesday, April 16, 2024 | 1:30 PM

Room 104 C/DThe logo for Cybin, featuring the word "Cybin" in a stylized, handwritten-style script font.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.

dentalcorp

Wednesday, April 17, 2024 | 2:00 PM
Room 104 C/D



dentalcorp is Canada's largest and one of North America's fastest growing networks of dental practices, committed to advancing the overall well-being of Canadians by delivering the best clinical outcomes and unforgettable experiences. dentalcorp acquires leading dental practices, uniting its network in a common goal: to be Canada's most trusted healthcare network. Leveraging its industry-leading technology, know-how and scale, dentalcorp offers professionals the unique opportunity to retain their clinical autonomy while unlocking their potential for future growth.

Domain Therapeutics

Wednesday, April 17, 2024 | 3:30 PM
Room 104 A



Domain Therapeutics is a global clinical-stage biopharmaceutical company operating in Strasbourg France, Boston and Montreal, focused on developing innovative immunotherapies targeting G Proteain-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer.

Domain is supported by leading international venture capital firms from Europe, Asia and North America and is currently raising a series B to leverage its next phase of growth and progress its unique pipeline.

As a leader in GPCRs in immuno-oncology, our ambition is to beat resistance to immune modulation in the tumor microenvironment and defeat cancer. Our goal is to unveil the therapeutic potential of GPCRs to deliver the next generation of immunotherapies. Two decades of growing expertise in GPCR drug discovery, validated by multiple pharma partnerships in several therapeutic area, and associated with a world class drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients.

DRI Healthcare Trust

Wednesday, April 17, 2024 | 10:30 AM
Room 104 C/D



DRI Healthcare Trust is managed by DRI Capital Inc. (“DRI Capital”), the pioneer in global pharmaceutical royalty monetization with a more than 30-year history of accelerating innovation by providing capital to inventors, academic institutions and biopharma companies. Since its founding in 1989, DRI Capital has deployed more than US\$3.0 billion, acquiring more than 70 royalties on 45-plus drugs, including Iylea, Keytruda, Orserdu, Spinraza, Stelara, Vonjo, Zejula and Zytiga.

Edesa Biotech

Wednesday, April 17, 2024 | 11:00 AM
Room 104 A



Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. Edesa is also planning to file an investigational new drug application for a future Phase 2 study of paridiprubart for pulmonary fibrosis. For its dermatology assets, the company has received regulatory approval to conduct a Phase 2 trial of its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. In addition, Edesa is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition.

enGene

Tuesday, April 16, 2024 | 3:00 PM

Room 104 C/D**enGene** 

enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lead program is EG-70 for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG) – a disease with a high clinical burden. EG-70 is being evaluated in an ongoing Phase 2 pivotal study. EG-70 was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

Entos Pharmaceuticals

Wednesday, April 17, 2024 | 3:00 PM

Room 104 A**entos** 
Pharmaceuticals

A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

ESSA Pharma

Tuesday, April 16, 2024 | 2:30 PM
Room 104 C/D



ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.

Eupraxia Pharmaceuticals

Tuesday, April 16, 2024 | 10:30 AM
Room 104 C/D



Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need.

The Company strives to provide improved patient benefit and has developed technology that delivers targeted, long-lasting activity with fewer side effects. Diffusphere™, a proprietary, polymer-based micro-sphere technology, facilitates targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable PK profiles. The technology can be used with multiple active pharmaceutical ingredients and delivery methods.

Eupraxia's lead product candidate, EP-104IAR, recently completed a Phase 2b clinical trial for the treatment of pain due to osteoarthritis of the knee. EP-104IAR met its primary endpoint and three of the four secondary endpoints. The EP-104 platform has expanded into gastrointestinal disease and has initiated a Phase 1b/2a program to treat EoE. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations.

Exact Imaging

Tuesday, April 16, 2024 | 2:30 PM

Room 104 B

Exact Imaging is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging's ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and target biopsies at those areas. For those cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates fast, simple MRI fusion-based targeting with the guidance of the micro-ultrasound system's 70-micron real-time resolution. The ExactVu micro-ultrasound system including the FusionVu application has received regulatory approval in the European Union, the United States, Canada, Japan, and Brazil.

Find Therapeutics

Wednesday, April 17, 2024 | 2:30 PM

Room 104 A

Find Therapeutics is dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases. The company was launched in 2020 with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics, and GPCR technology and know-how from Peptimimesis Pharma.

FORUS Therapeutics

Tuesday, April 16, 2024 | 9:30 AM

Room 104 A

FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer. Our mission is to bring solutions to cancer patients, caregivers, physicians and our partners by accelerating unique and important treatments that meaningfully enhance life.

Gandeeva Therapeutics

Wednesday, April 17, 2024 | 2:00 PM

Room 104 A

Gandeeva Therapeutics is a precision medicine company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva's structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline targeting difficult-to-treat cancers with novel protein interaction modulators such as interfacial glues (iGlues™) and allosteric inhibitors. Gandeeva is headquartered in the Greater Vancouver area, Canada.

Grey Wolf Animal Health

Wednesday, April 17, 2024 | 3:00 PM

Room 104 B

Grey Wolf Animal Health Corp. is a diversified animal health company founded by a veterinarian to bring to market a broad portfolio of products that meets the unmet needs of veterinarians, clinics and pets. The Company's strategy is to in-license, acquire or compound innovative prescription and non-prescription products for commercialization in the veterinarian channel in Canada. Over the past 5 years, Grey Wolf has expanded commercial operations across Canada, launched 11 products and completed 2 accretive strategic acquisitions. We are a cash flow positive company and have a solid balance sheet to support future growth initiatives.

Hamilton Thorne

Tuesday, April 16, 2024 | 10:00 AM

Room 104 B

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, Gynetics, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

HEALWELL AI

Wednesday, April 17, 2024 | 3:30 PM

Room 104 C/D**H E A L W E L L A I**

HEALWELL AI is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve health care and save lives through early identification and detection of disease. As a physician-led organization with a proven management team of experienced executives, HEALWELL AI is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map.

SPECIALTY PHARMACEUTICALS**TSX: HLS****HLS Therapeutics**

Wednesday, April 17, 2024 | 2:00 PM

Room 104 B

HLS Therapeutics Inc.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.

Intellijoint SurgicalTuesday, April 16, 2024 | 11:00 AM
Room 104 B

Intellijoint Surgical develops and commercializes surgical planning & navigation solutions for total hip and knee joint replacements. It is committed to improving patients' lives by providing every surgeon with effective, easy-to-use technology. Intellijoint's technology is used by top orthopaedic institutions and surgeons globally.

KalGeneWednesday, April 17, 2024 | 11:30 AM
Room 104 A**KALGENE INC**

KalGene Inc., is a late preclinical Alzheimer's therapeutic company with a proprietary drug candidate called KG207. KG207 is a reverse engineered fusion protein designed by 40+ scientists at the National Research Council of Canada. We believe the molecule has best in class potential for the treatment of Alzheimer's patients based on its 3 main elements, namely the proprietary active crossing of the Blood Brain Barrier; a modified IgG1-FC fusion protein domain; and proprietary optimized specificity for toxic oligomeric species of ABeta.

The validation of KG207 includes head to head animal studies comparing it to approved MABs (Aduhelm and Leqembi) for Aria E/H or cerebral inflammation. Further it was the subject of a McGill transgenic rat model which was recently identified by an independent review paper as one of the best examples of translation into human studies. Finally, KG207 demonstrated in an invitro model, that because it is not an MAB, it does not elicit a TNF alpha or IL6 cytokine storm, resulting in a lack of inflammatory activation by microglial sequestration of bound complex through the CSF.

Knight TherapeuticsTuesday, April 16, 2024 | 10:30 AM
Room 104 A

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM.

Kye PharmaceuticalsTuesday, April 16, 2024 | 10:00 AM
Room 104 A

Kye (pronounced “kai”) is a growth-stage Canadian specialty pharmaceutical company committed to bringing value to Canadians by identifying, licensing and commercializing novel prescription medicines that may not otherwise be available to patients across Canada. Fueled by courage and agility, our people and corporate philosophy are rooted in the pursuit of innovation and driven by our entrepreneurial spirit.

“Kye” is a Gaelic word meaning the “holder of keys”. At Kye, we recognize the importance of advancing access to innovative healthcare solutions and unlocking better outcomes for Canadians.

SPECIALTY PHARMACEUTICALS

TSX-V: LSL**LSL Pharma Group**

Wednesday, April 17, 2024 | 4:00 PM

Room 104 C/D

LSL Pharma Group is an integrated Canadian pharmaceutical company specializing in the development, manufacture, and commercialization of high-quality sterile ophthalmic pharmaceuticals for the Canadian, US and global markets. The Corporation also manufactures under contract (CDMO), a full suite of solid-dose products, such as tablets, capsules, bags and others.

SPECIALTY PHARMACEUTICALS

TSX: MDP**Medexus Pharma**

Wednesday, April 17, 2024 | 1:30 PM

Room 104 B

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.

Medicenna Therapeutics

Tuesday, April 16, 2024 | 11:00 AM
Room 104 C/D



Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class empowered superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) with no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna's early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically "cold" tumors.

Mesentech

Wednesday, April 17, 2024 | 4:00 PM
Room 104 A



Mesentech is a biotechnology company developing new therapies to treat diseases and conditions of the bone using tissue selective technologies. Its lead candidate MES1022 is a bone-selective EP4-agonist for fracture healing. Other pipeline programs utilizing tissue-targeting prodrug technology are in development for bone cancers, and osseointegration of orthopedic implants. Mesentech is headquartered in Vancouver, British Columbia.

Microbix Biosystems

Tuesday, April 16, 2024 | 10:30 AM

Room 104 B

Microbix Biosystems Inc. creates proprietary biological products for human health, with over 100 skilled employees and annualized sales now targeting C\$ 2.0 million per month. It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of 10 international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport medium (DxTM™) to stabilize patient samples for lab-based molecular diagnostic testing and Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots.

NeuPath Health

Wednesday, April 17, 2024 | 11:00 AM

Room 104 B

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual we treat to live their best life.

Newtopia

Wednesday, April 17, 2024 | 11:30 AM
Room 104 B



Newtopia is a tech-enabled habit change provider focused on disease prevention and reducing the cost of care for health insurers. As a provider of whole person care, we prevent, reverse and slow the progression of chronic disease while enriching mental health, resilience and overall human performance. Newtopia's programs leverage genetic, social and behavioral insights to create individualized prevention programs with a focus on type 2 diabetes, heart disease, stroke and weight. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes.

Notch Therapeutics

Wednesday, April 17, 2024 | 1:30 PM
Room 104 A



Notch is an early-stage biotechnology company working to maximize the benefit of cell therapies through a proprietary T cell-production platform that combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch's iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design and manufacture a uniform and unlimited supply of therapeutic T cells.

Orpyx

Tuesday, April 16, 2024 | 4:00 PM

Room 104 B

Orpyx is a med tech + touch company focused on revolutionizing diabetic limb management. Its proprietary Orpyx SI® Sensory Insole platform offers unparalleled technology for preventing diabetic foot ulcers and amputations. The program combines wearable sensors with real-time feedback, and analytics-driven remote care to improve foot health and prevent diabetic foot ulcers, which account for \$60 billion in diabetes care costs (one-third the direct cost of diabetes care annually).

Panthera Dental

Tuesday, April 16, 2024 | 3:00 PM

Room 104 B

Panthera Dental is committed to design and manufacture custom-made dental restorations, sleep breathing disorder solutions and implantology products using proprietary CAD/CAM processes, smart manufacturing and superior quality materials.

Panthera's highly skilled and passionate team is dedicated to provide the highest quality outcomes and to deliver state-of-the-art solutions to dental, medical and sleep professionals who strive to improve patients' quality of life worldwide.

Pharmascience

Wednesday, April 17, 2024 | 9:30 AM
Room 104 C/D



Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 52nd among Canada's top 100 Research & Development (R&D) investors in 2023, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada.

Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life.

MEDICAL TECHNOLOGY

NASDAQ: PROF / TSX: PRN

Profound Medical

Tuesday, April 16, 2024 | 9:30 AM
Room 104 B



Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration ("FDA"). Profound is also commercializing Sonallevé®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonallevé® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonallevé® where the technology has been shown to have clinical application.

ProMIS NeurosciencesWednesday, April 17, 2024 | 10:30 AM
Room 104 A

ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts.

Repare TherapeuticsTuesday, April 16, 2024 | 3:30 PM
Room 104 C/D

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; RP-1664, a preclinical PLK4 inhibitor; RP-3467, a preclinical Pol inhibitor program; as well as additional, undisclosed preclinical programs.

Satellos Bioscience

Tuesday, April 16, 2024 | 11:30 AM
Room 104 C/D



Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body's innate muscle repair and regeneration process. The Company's lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario.

Searchlight Pharma

Wednesday, April 17, 2024 | 10:00 AM
Room 104 C/D



Searchlight Pharma Inc., headquartered in Montreal, is a leading Canadian-based specialty healthcare company with global reach that executes best-in-class search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products.

BIOTECHNOLOGY

TSX: SVA**Sernova**

Wednesday, April 17, 2024 | 9:30 AM

Room 104 A

Sernova is a clinical-stage biotechnology company that is advancing a novel cell therapy platform for the treatment of chronic diseases. Our lead program is evaluating our Cell Pouch System™ as a potential ‘functional cure’ for insulin-dependent diabetes. In addition, we have a robust pipeline that includes preclinical programs in hemophilia A and hypothyroidism.

HEALTHCARE SERVICES/DIGITAL HEALTH

PRIVATE**SRx Health Solutions**

Wednesday, April 17, 2024 | 10:30 AM

Room 104 B

SRx Health Solutions is an integrated Canadian health care services provider that operates within the specialty healthcare industry. The SRx network extends across all ten Canadian provinces, making it one of the most accessible providers of comprehensive, integrated, and customized specialty healthcare services in the country. SRx combines years of industry knowledge, technology, and patient-centric excellence to create strategies and solutions that consistently exceed client expectations and drive critical patient care initiatives aimed to improve the wellness of Canadians.

Synaptive Medical

Tuesday, April 16, 2024 | 11:30 AM
Room 104 B

The logo for Synaptive, featuring the word "Synaptive" in a bold, black, sans-serif font.

Synaptive Medical Inc., a Toronto-based, high growth global medical technology company, solves surgical, imaging, and data challenges to improve the quality of human lives. Synaptive's integrated suite of products – bridging MRI, surgical planning, navigation, and robotic visualization – delivers patient-centric information with automated efficiency across all stages of clinical interventions.

Theratechnologies

Wednesday, April 17, 2024 | 10:00 AM
Room 104 A



Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

Thryv Therapeutics

Tuesday, April 16, 2024 | 3:00 PM

Room 104 A

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat Congenital Long QT Syndromes (LQTS), atrial fibrillation, heart failure and resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1).

Valeo Pharma

Wednesday, April 17, 2024 | 4:00 PM

Room 104 B

Valeo Pharma is a fast-growing Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

Ventus Therapeutics

Tuesday April 16, 2024 | 11:30 AM

Room 104 A



Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying leading-edge structural biology and computational chemistry tools to create novel small molecule medicines for challenging targets in immunology, inflammation, and neurology. The company's proprietary drug discovery platform, ReSOLVETM, gives it the ability to discover and develop medicines through unique insights into protein targets and to create dynamic hydrocophore™ blueprints that can guide the development of differentiated therapies at a fast pace. Ventus' first target screen was conducted in 2020, which led to the nomination of three development candidates in 2022, including: VENT-03, a first-in-class cGAS inhibitor; VENT-02, a brain-penetrant NLRP3 inhibitor; and VENT-01, a peripherally restricted NLRP3 inhibitor. Ventus entered the clinic with its two most advanced programs, VENT-02 and VENT-03, in 2023, and the Phase 1 clinical trials are ongoing. These programs exemplify Ventus' robust discovery capabilities and focus on differentiated programs for multi-indication immunology and neurology targets.

Virica Biotech

Tuesday, April 16, 2024 | 1:30 PM

Room 104 B



Virica develops cell enhancers for viral vectors that improve the yield and quality of vaccines and cell and gene therapies, allowing developers to economically deploy their products at scale. Virica's Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by anti-viral defenses in manufacturing cells. Purpose formulated VSE combinations substantially increase manufacturing yields and reduce the cost of goods for a range of life-changing products, including vaccines, gene therapies, and cell therapies.

VitalHub

Wednesday, April 17, 2024 | 2:30 PM

Room 104 C/D

Software for Health and Human Services providers designed to simplify the user experience and optimize outcomes.

VitalHub Corp. provides technology to Health and Human Services providers including Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination & Optimization, and Patient Flow & Operational Visibility solutions.

The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive merger and acquisition ("M&A") plan. Currently VitalHub serves more than 1,000 clients across Canada, USA, UK, Australia, the Middle East, and Europe. VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The VitalHub team comprises more than 350 team members globally.

WELL Health Technologies

Wednesday, April 17, 2024 | 1:30 PM

Room 104 C/D**WELL Health**
TECHNOLOGIES CORP

WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 33,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 165 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, mental health, revenue cycle management, and practitioner recruiting.

Xediton Pharmaceuticals

Wednesday, April 17, 2024 | 11:00 AM
Room 104 C/D



Xediton Pharmaceuticals is a privately-held specialty pharmaceutical company with a focus on meeting the needs of patients, physicians and partners. Xediton Pharmaceuticals is committed to developing, partnering and making available new and established medicines to promote the health of Canadians. Located in the Greater Toronto Area, Canada, Xediton Pharmaceuticals has products in Oncology, Anti-Infectives, Pain, CNS, GI, Ophthalmology, Renal and CV and has built strong strategic alliances with Global and International Healthcare and pharmaceutical companies.

Xenon Pharmaceuticals

Tuesday, April 16, 2024 | 9:30 AM
Room 104 C/D



Xenon Pharmaceuticals is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need.

Zucara TherapeuticsTuesday, April 16, 2024 | 2:30 PM
Room 104 A

Zucara Therapeutics is developing ZT-01, a first-in-class, once-daily therapeutic to prevent hypoglycemia in people with T1D and insulin-dependent Type 2 diabetes. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with these conditions. ZT-01 is designed to restore glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life.

ZymeworksTuesday, April 16, 2024 | 2:00 PM
Room 104 C/D

Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies.





bloom burton & co

ABOUT BLOOM BURTON & CO.

FOR 15 YEARS, BLOOM BURTON HAS SERVED CANADIAN HEALTHCARE INVESTORS AND COMPANIES...

Our team has deep knowledge in medicine, science, finance, and healthcare invention, development and commercialization. We are the ideal group to help companies plan their capital market strategies, investigate the relevance of new biological pathways, consider new therapeutic indications and clinical designs, as well as catalogue and conduct due diligence on new products or companies for acquisition. By speaking with large companies and investors every day, **we know what they are looking for.**

We identify the most impactful companies for our investor network and we provide tailor-made support solutions for management teams and boards of healthcare companies.



WE CONTINUE TO SERVE INVESTORS AND COMPANIES SEEKING TO MAKE AN IMPACT IN HEALTHCARE AND BIOTECH.

M&A Transaction

APOTEX

Canadian-Based
Global Health Company

To acquire

SEARCHLIGHT
PHARMA

April 2024

Advisor to Searchlight Pharma Inc.

Private Placement

US \$150,000,000

Cybin

March 2024

Lead Agent to Cybin

Fairness Opinion

US \$16,000,000

CEAPRO
Natural Sciences LP

Announces merger with

ÆTERNA
ZENTARIS

December 2023

Advisor to Ceapro

15

tb

BLOOM BURTON & CO.
15TH ANNIVERSARY

Advisory

US \$1,075,000,000

novo nordisk

Completes acquisition of

inversago
PHARMA

September 2023

Advisor to Inversago

Fairness Opinion

US \$2,000,000,000

GSK

Completes acquisition of

Bellus
HEALTH

June 2023

Advisor to Bellus Health

Public Offering

CDN \$55,000,000

satellos

May 2023

Sole Agent to Satellos Bioscience

M&A Transaction Debt Financing

juno.

PHARMACEUTICALS CANADA

Completes acquisition of

omega

May 2023

Advisor to Juno Pharmaceuticals

M&A Transaction

CDN \$85,000,000*

*Enterprise Value

SEARCHLIGHT
PHARMA

Completes acquisition of

MIRAVO

March 2023

Advisor to Miravo Healthcare

Strategic Advisory

adMare
BIODINNOVATIONS

October 2022

Advisor

SERVICES



Our services help **identify, cultivate and create investment opportunities** in the healthcare sector on behalf of companies and investors.

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, digital health, life science tools, animal health, nutrition and wellness.

OUR SIX BUSINESS SERVICES WORK COHESIVELY TO ACCELERATE MONETIZATION FOR BOTH COMPANY AND INVESTOR CLIENTS.

1

RAISING CAPITAL & FINANCING

Sourcing equity and debt capital for private and public companies

2

M&A ADVISORY

Enabling monetization through strategic transactions

3

EQUITY RESEARCH

Influential opinions and insights on companies

4

SALES & TRADING

Generating returns for investors

5

STRATEGIC ADVISORY

Scientific and business advisory services

6

COMPANY CREATION

Establishing and incubating new healthcare companies

SPONSORS



mccarthy
tetraault

M
MINTZ

newsfile

NORTON ROSE
FULBRIGHT

TMX THE FUTURE
IS YOURS TO SEE.

TORYS
LLP

troutman
pepper

Zeifmans
Ideas with impact

THANK YOU TO OUR 2024 SPONSORS FOR
YOUR GENEROUS SUPPORT!

CONFERENCE INFORMATION

COMPANY PRESENTATIONS

- Room 104 A
- Room 104 B
- Room 104 C/D

1X1 MEETINGS

- Room 105

KEYNOTE ADDRESS AND PANEL DISCUSSIONS

- Plenary Room 106/107

QUESTIONS OR LOST AND FOUND

- Registration Booth

SUBMIT YOUR FEEDBACK

for a chance to win a CAD \$50 Amazon gift card.




WI-FI

Network Name

Bloom Burton & Co.

Access Code

BBHIC2024





2024
BLOOM
BURTON
Award
GALA

September 26, 2024

The Ritz-Carlton
Toronto, Ontario
181 Wellington St W
M5V 3G7

SPONSORSHIP CONTACT
BBLOOM@BLOOMBURTON.COM





bloom burton & co

/accelerating returns in healthcare[®]



#BBHIC2024



@bloomburton



Bloom Burton & Co.



Regulated by CIRO
Canadian Investment
Regulatory Organization

CIPF
Canadian Investor Protection Fund
MEMBER